Market Cap 16.84M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,765,327
Avg Vol 14,877,256
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 31%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
Zergg
Zergg Oct. 25 at 12:15 AM
$CLRB long term bullish
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 24 at 2:31 PM
$RADX RAD402 formed between MD anderson and Radiopharm Theranostics will enter the clinic end of year for Prostate Cancer. MD Anderson is the best cancer center in the world. $ATNM $LNTH $CLRB $CATX
1 · Reply
EvenBetter99
EvenBetter99 Oct. 24 at 2:18 PM
$CLRB Diamond - look ahead
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 23 at 4:26 PM
$CLRB bag holder laughing to cover up the pain. ☺️
1 · Reply
elmono
elmono Oct. 23 at 4:24 PM
$CLRB making good money on short…yes? 😂😂😂
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 23 at 3:54 PM
$CLRB down down down. where it stops nobody knows.
0 · Reply
Siuolman58
Siuolman58 Oct. 23 at 3:16 PM
$CLRB I personally think thru my research is that when the 1 million shares that were provided thru warrants are sold they will be done with the selling.
3 · Reply
ObsOlet
ObsOlet Oct. 23 at 3:14 PM
$CLRB My conclusion: Share price/market capitalization adjusts to the new number of shares. Cellectar will now have approximately $17 million in cash. What comes next? I expect: - LTE data/subanalyses on iopofosine in WM post-BTKi treatment. In addition, emphasis on a 2-line therapy. As well as presentation of the data at the upcoming ASH 2025 Congress (early December 6-9) - Start of P1b study on TNBC (CLR 125 Phase 1b) - Q3 financial results & outlook (early November) - Read-out of P2 study (CLOVER / Iopofosine) on B-cell malignancies (Dec. 2025 or Q1-2026) AND (asap): Partner deal for P3 study with Iopofosine in WM and/or PDC platform deal (global or local)
0 · Reply
ObsOlet
ObsOlet Oct. 23 at 2:41 PM
$CLRB The sharp decline in the share price in recent days is in line with the original market capitalization prior to the capital increase.... According to the latest SEC filing, there are now 6,336,322 shares "outstanding" (including the two convertible bonds). This means that at a share price of $3.90 x 6.34 million shares = approx. $25.0 million market capitalization. Before the capital increase and the good news from the EMA ("go" EU filing), the share price was USD 6.0 x 3.3 million shares = USD 20.0 million market capitalization. So we should now be at roughly the same market capitalization plus a small revaluation of USD +5 million, if it stays that way! Ultimately, the share price already factors in the +2.0 million convertible shares at $6, even though these have not yet been exercised. I hope the storm is over an we get the LTE-data on iopofosine in WM for the FDA!!
1 · Reply
Siuolman58
Siuolman58 Oct. 23 at 11:05 AM
$CLRB The fund that converted the warrants will soon be done selling.
0 · Reply
Latest News on CLRB
Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 6 months ago

Cellectar Announces Plan to Explore Strategic Alternatives


Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 12:41 PM EDT - 8 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript


Zergg
Zergg Oct. 25 at 12:15 AM
$CLRB long term bullish
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 24 at 2:31 PM
$RADX RAD402 formed between MD anderson and Radiopharm Theranostics will enter the clinic end of year for Prostate Cancer. MD Anderson is the best cancer center in the world. $ATNM $LNTH $CLRB $CATX
1 · Reply
EvenBetter99
EvenBetter99 Oct. 24 at 2:18 PM
$CLRB Diamond - look ahead
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 23 at 4:26 PM
$CLRB bag holder laughing to cover up the pain. ☺️
1 · Reply
elmono
elmono Oct. 23 at 4:24 PM
$CLRB making good money on short…yes? 😂😂😂
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 23 at 3:54 PM
$CLRB down down down. where it stops nobody knows.
0 · Reply
Siuolman58
Siuolman58 Oct. 23 at 3:16 PM
$CLRB I personally think thru my research is that when the 1 million shares that were provided thru warrants are sold they will be done with the selling.
3 · Reply
ObsOlet
ObsOlet Oct. 23 at 3:14 PM
$CLRB My conclusion: Share price/market capitalization adjusts to the new number of shares. Cellectar will now have approximately $17 million in cash. What comes next? I expect: - LTE data/subanalyses on iopofosine in WM post-BTKi treatment. In addition, emphasis on a 2-line therapy. As well as presentation of the data at the upcoming ASH 2025 Congress (early December 6-9) - Start of P1b study on TNBC (CLR 125 Phase 1b) - Q3 financial results & outlook (early November) - Read-out of P2 study (CLOVER / Iopofosine) on B-cell malignancies (Dec. 2025 or Q1-2026) AND (asap): Partner deal for P3 study with Iopofosine in WM and/or PDC platform deal (global or local)
0 · Reply
ObsOlet
ObsOlet Oct. 23 at 2:41 PM
$CLRB The sharp decline in the share price in recent days is in line with the original market capitalization prior to the capital increase.... According to the latest SEC filing, there are now 6,336,322 shares "outstanding" (including the two convertible bonds). This means that at a share price of $3.90 x 6.34 million shares = approx. $25.0 million market capitalization. Before the capital increase and the good news from the EMA ("go" EU filing), the share price was USD 6.0 x 3.3 million shares = USD 20.0 million market capitalization. So we should now be at roughly the same market capitalization plus a small revaluation of USD +5 million, if it stays that way! Ultimately, the share price already factors in the +2.0 million convertible shares at $6, even though these have not yet been exercised. I hope the storm is over an we get the LTE-data on iopofosine in WM for the FDA!!
1 · Reply
Siuolman58
Siuolman58 Oct. 23 at 11:05 AM
$CLRB The fund that converted the warrants will soon be done selling.
0 · Reply
Aawilliam2003
Aawilliam2003 Oct. 22 at 8:17 PM
$CLRB now down 98.91% over 5 years. You have to try hard to be that bad. Congrats to the CLRB team of dimwits
1 · Reply
Zergg
Zergg Oct. 22 at 7:38 PM
$CLRB we cooked?
1 · Reply
CasperPuff
CasperPuff Oct. 22 at 7:29 PM
$CLRB why you go down?
1 · Reply
RunningTime2025
RunningTime2025 Oct. 22 at 7:01 PM
$CLRB possibility going back OTC….?
1 · Reply
Siuolman58
Siuolman58 Oct. 22 at 4:51 PM
$CLRB You’re likely spot-on— the recent slow, low-volume declines in $CLRB trading do have the fingerprints of an algorithmic accumulation pattern rather than typical retail selling.
0 · Reply
EvenBetter99
EvenBetter99 Oct. 22 at 4:51 PM
$CLRB nice entry
0 · Reply
Siuolman58
Siuolman58 Oct. 22 at 4:37 PM
$CLRB Investor Relations by phone at (608) 441-8120.
0 · Reply
vlentini
vlentini Oct. 22 at 2:54 PM
$CLRB Ci vediamo a meno di 1 S fra qualche mese, l' ingordigia non fa mai bene!! Non si può fare da soli quello che è già difficile fare insieme ad altri.
1 · Reply
Siuolman58
Siuolman58 Oct. 22 at 2:35 PM
$CLRB The never ending sellllling continues! No volume but nevertheless all selling
1 · Reply
Scorpole
Scorpole Oct. 22 at 1:42 PM
$CLRB New ATL
0 · Reply
Scorpole
Scorpole Oct. 22 at 1:41 PM
$CLRB Those who sell or short must have enough inside information that they do not need to be afraid of a partnership agreement or BO.
0 · Reply
Siuolman58
Siuolman58 Oct. 21 at 11:56 PM
$CLRB Tomorrow is the day to buy! Tomorrow is the day to go all in!
0 · Reply